Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome (MDS)
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
Chronic anemia is the symptom most frequently found at diagnosis in low risk myelodysplastic
syndrome. It generates an increased rate of morbidity and mortality in this population of
patients whose median age is high and the rate of co-mobidities important. The historical
treatment is limited to transfusion support with a significant impact on quality of life and
the incidence of secondary haemosiderosis, which contributes to the emergence of
co-morbidities, especially cardiovascular. Treatment with rHuEPO allows for overall erythroid
response in 40-60% of patients treated.
In this trial, the investigators intend to study the interest of a treatment with epoetin
beta in patients with anemia <10 g / dL in the context of a myelodysplastic syndrome with
IPSS score <1.
In addition to studying the erythroid response, the investigators will measure the impact on
quality of life and functional performance.
Patients will receive epoetin beta (60 000UI/week). Response will be assessed after 12 and 24
weeks of treatment.